New Delhi Pricing of medical devices and ban on 344 fixed dose combinations (FDC) drugs are likely to top the agenda of Prime Minister Narendra Modi when he meets heads of pharma companies on Tuesday in Washington DC.
US-based companies including Phensedyl maker Abbott, Corex producer Pfizer, and medical device maker Zimmer among several others are set to push their concerns through the US India Business Council (USIBC).
Modi, who is on a five-nation tour, will meet 20-odd CEOs including those from the health and pharma sector. Apart from Abbott’s Miles White and Pfizer’s Ian C Read, Amazon’s Jeff Bezos, PepsiCo’s Indra Nooyi, Cisco’s John Chambers, Mastercard’s Ajay Banga, Boeing’s Dennis Muilenburg, Lockheed’ s Marillyn Hewson, American Tower Corp’s James Taiclet and Pincus’ Joseph P Landy are expected to meet Modi.
“Abbott is expected to raise issues over pricing of stents in India whereas Pfizer may raise the issue of FDC ban,” a source familiar with the development said. USIBC refused to comment. Meanwhile, foreign drugmakers lobby group Organisation of Pharmaceutical Producers of India (OPPI) said that the pharmaceutical industry will be seeking a fair, predictable and transparent investment climate in India.